home / stock / ltrn / ltrn short
Short Information | Lantern Pharma Inc. (NASDAQ:LTRN)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 293,637 |
Total Actual Volume | 1,562,720 |
Short Trends | |
---|---|
Cover Days | 19 |
Short Days | 0 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 14,682 |
Average Short Percentage | 19.10% |
Is there a LTRN Short Squeeze or Breakout about to happen?
See the LTRN Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-05-2024 | $4.25 | $4.38 | $4.57 | $4.25 | 17,695 | 2,845 | 16.08% |
07-03-2024 | $4.38 | $4.29 | $4.57 | $4.25 | 25,523 | 3,860 | 15.12% |
07-02-2024 | $4.47 | $4.4 | $4.68 | $4.4 | 21,948 | 2,729 | 12.43% |
07-01-2024 | $4.76 | $4.52 | $4.9 | $4.4 | 40,541 | 9,744 | 24.03% |
06-28-2024 | $4.56 | $4.67 | $4.868 | $4.51 | 78,201 | 28,794 | 36.82% |
06-27-2024 | $4.25 | $4.54 | $4.61 | $4.24 | 43,924 | 12,451 | 28.35% |
06-26-2024 | $4 | $4.27 | $4.29 | $4 | 48,823 | 11,420 | 23.39% |
06-25-2024 | $3.87 | $4.01 | $4.15 | $3.83 | 66,386 | 15,703 | 23.65% |
06-24-2024 | $4.14 | $3.91 | $4.21 | $3.85 | 160,586 | 28,442 | 17.71% |
06-21-2024 | $4.42 | $4.15 | $4.64 | $4.1 | 117,697 | 26,287 | 22.33% |
06-20-2024 | $4.61 | $4.44 | $4.61 | $4.32 | 107,542 | 18,952 | 17.62% |
06-18-2024 | $4.84 | $4.69 | $4.88 | $4.5801 | 105,336 | 17,933 | 17.02% |
06-17-2024 | $5.25 | $4.91 | $5.25 | $4.77 | 125,000 | 29,106 | 23.28% |
06-14-2024 | $5.41 | $5.37 | $5.56 | $5.15 | 80,923 | 5,835 | 7.21% |
06-13-2024 | $5.64 | $5.44 | $5.64 | $5.25 | 37,205 | 4,988 | 13.41% |
06-12-2024 | $5.65 | $5.65 | $5.86 | $5.4437 | 59,518 | 9,097 | 15.28% |
06-11-2024 | $5.29 | $5.59 | $5.66 | $5.26 | 116,569 | 14,671 | 12.59% |
06-10-2024 | $5.55 | $5.4 | $5.635 | $5.25 | 159,527 | 17,020 | 10.67% |
06-07-2024 | $5.73 | $5.58 | $5.89 | $5.55 | 63,717 | 14,286 | 22.42% |
06-06-2024 | $6.06 | $5.81 | $6.06 | $5.68 | 86,059 | 19,474 | 22.63% |
News, Short Squeeze, Breakout and More Instantly...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...
XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development. The AI-enabled collabo...